

4/7,K/14 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

05942697 EMBASE No: 1994346987
Antibodies to high mobility group proteins in systemic sclerosis
Ayer L.M.; Senecal J.-L.; Martin L.; Dixon G.H.; Fritzler M.J.
Faculty of Medicine, University of Calgary, 3330 Hospital Dr.
N.W., Calgary, Alta. T2N 4N1 Canada
Journal of Rheumatology (J. RHEUMATOL.) (Canada) 1994, 21/11
(2071-2075)
CODEN: JRHUA ISSN: 0315-162X
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Objective. To determine the prevalence of autoantibodies to high mobility group (HMG) proteins in systemic sclerosis (SSc). Methods. One hundred ninety-seven unselected sera from patients diagnosed as SSc (n = 180) or Raynaud's phenomenon (RP) (n = 17) were tested for HMG autoantibodies by ELISA and immunoblotting. Results. Seventy-one of the 180 (39.0%) SSc sera bound to HMG proteins in an ELISA: 56 (31%) to **HMG-1** and/or **HMG-2**; 29 (16%) to HMG-14/17. In the same assay 7 of 17 RP sera (41%) bound to HMG proteins: 4 (23%) to **HMG-1** and/or **HMG-2**, and 5 (29%) to HMG-14/17. The specificity of HMG binding was confirmed by immunoblotting. Conclusion. Antibodies to HMG proteins, particularly to **HMG-1** and **HMG-2** are found in about 1/3 of SSc sera. Since **HMG-1** and **HMG-2** have a role in transcription, these observations further implicate transcriptional complexes as targets of autoantibodies in scleroderma. This is the first published report of HMG autoantibodies in scleroderma.

21
21, 28, 31

2

S1	3268	HMG(W) (1 OR 2) OR HIGH(W)MOBILITY (W) GROUP (W) PROTEIN
S2	183669	AUTOIMMUNE OR AUTOIMMUNITY
S3	29	S1 AND S2
S4	20	RD (unique items)
S5	0	S1 AND KIT
?		